Cyfuse Biomedical K.K. Logo

Cyfuse Biomedical K.K.

Develops scaffold-free bio 3D printing technology for tissue and organ fabrication.

4892 | T

Overview

Corporate Details

ISIN(s):
JP3311800001
LEI:
Country:
Japan
Address:
港区三田3−5−27 住友不動産三田ツインビル西館

Description

Cyfuse Biomedical K.K. is a research and development company specializing in regenerative medicine through its proprietary bio 3D printing platform technology. The company's core innovation is a scaffold-free method for fabricating three-dimensional tissues and organs by fusing cellular aggregates, known as spheroids. This approach allows for the creation of complex biological structures using cells exclusively. Cyfuse develops, manufactures, and commercializes its bio 3D printers, including the Regenova® and S-PIKE® systems. These technologies are aimed at advancing applications in drug discovery, preclinical research, and the development of cellular products for therapeutic tissue and organ regeneration.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 08:31
確認書
Japanese 9.0 KB
2025-08-14 08:30
半期報告書-第16期(2025/01/01-2025/12/31)
Japanese 359.3 KB
2025-05-30 08:30
有価証券届出書(組込方式)
Japanese 924.1 KB
2025-03-26 03:03
臨時報告書
Japanese 21.4 KB
2025-03-26 03:02
内部統制報告書-第15期(2024/01/01-2024/12/31)
Japanese 22.7 KB
2025-03-26 03:01
有価証券報告書-第15期(2024/01/01-2024/12/31)
Japanese 2.2 MB
2025-03-26 03:01
確認書
Japanese 9.0 KB
2025-02-25 08:30
臨時報告書
Japanese 20.6 KB
2024-08-14 08:33
確認書
Japanese 9.0 KB
2024-08-14 08:32
半期報告書-第15期(2024/01/01-2024/12/31)
Japanese 234.3 KB
2024-05-15 09:16
確認書
Japanese 9.0 KB
2024-05-15 09:15
四半期報告書-第15期第1四半期(2024/01/01-2024/03/31)
Japanese 196.4 KB
2024-04-17 10:10
臨時報告書
Japanese 43.2 KB
2024-03-27 08:18
臨時報告書
Japanese 23.2 KB
2024-03-27 08:17
内部統制報告書-第14期(2023/01/01-2023/12/31)
Japanese 22.8 KB

Automate Your Workflow. Get a real-time feed of all Cyfuse Biomedical K.K. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cyfuse Biomedical K.K.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cyfuse Biomedical K.K. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.